MedTrace Logo

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

NCT00381095 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2021-01-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the analgesic efficacy of flexibly-dosed pregabalin in the adjunctive treatment of subjects with cancer-induced bone pain.

Conditions

  • Bone Neoplasms
  • Pain, Intractable
  • Cancer

Interventions

DRUG

Pregabalin

Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States
  • Canada
  • Czechia
  • Egypt
  • Finland
  • France
  • Hungary
  • Italy
  • Mexico
  • Peru
  • Philippines
  • Poland
  • Russia
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Thailand
  • Venezuela

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00381095 on ClinicalTrials.gov